---
edited: 2024-03-02
tags:
---
### Etiology
- Benign growth hormone-secreting pituitary adenoma (> 95% of cases) [2]
- Very rare: neuroendocrine or hypothalamic tumors, paraneoplastic syndromes
	- Ectopic secretion of growth hormone by [[Neuroendocrine tumors]] (e.g., small cell lung carcinoma, pancreatic islet-cell tumor (as found in MEN1)
	- ↑ Secretion of growth hormone-releasing hormone (GHRH) from a hypothalamic tumor or in paraneoplastic syndromes (e.g., small cell lung carcinoma, medullary thyroid cancer) 
### Pathophysiology
- GH stimulates [[IGF-1]] (measured to assess acromegaly)
- [[Space Occupying Lesion]]: Causes compression of optic chaism and rest of pituitary and leads to decreased production of other hormones
### Clinical presentation
Here's a table summarizing the effects of tumor mass, soft tissue, and skeletal effects:

| System             | Effects                                                                                                                                                                                                                                                                                  |
| ------------------ | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| Tumor Mass         | - Headache <br> - Vision loss (bitemporal hemianopsia) <br> - Cranial nerve palsies <br> - Oligomenorrhea, secondary amenorrhea, galactorrhea (♀) due to deficient gonadotrophins<br> - Erectile dysfunction, decreased libido, decreased testicular volume (♂) deficient gonadotrophins |
| Soft Tissue growth | - Doughy skin texture <br> - Hyperhidrosis <br> - Deepening of the voice <br> - [[Macroglossia]] with fissures <br> - [[Obstructive sleep apnea]]                                                                                                                                        |
| Skeletal Effects   | - Coarsening of facial features (enlarged nose, forehead, and jaw with diastema) <br> - Widened hands, fingers, and feet , widening of teeth spaces due to jaw enlargement <br> - Painful arthropathy (ankles, knees, hips, spine)                                                       |
### Diagnosis

| Test                                | Description                                                                                                                                                                |
| ----------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| Serum IGF-1 concentration           | - The best single test <br> - Elevated IGF-1 level: acromegaly suspected; conduct OGTT <br> - Normal IGF-1 level: acromegaly ruled out                                     |
| OGTT with baseline GH and 2-hour GH | - The most specific test <br> - If GH suppressed: acromegaly ruled out <br> - If GH not suppressed: confirmed acromegaly; conduct pituitary MRI to determine source of GH  |
| Pituitary MRI                       | - Imaging modality of choice <br> - Usually shows a visible mass: confirmed GH-secreting pituitary adenoma <br> - If normal: screen for extrapituitary cause               |

### Complications
- [[Insulin resistance]] and [[Diabetes Mellitus]]
- [[Hypertension]]
	- [[LV hypertrophy]] and Cardiomyopathy
	- [[Arrhythmias]]
	- Valvular diseases
- [[Colonic cancers]]
- [[Thyroid cancers]]
- [[Median nerve compression]] in Carpal tunnel
- [[Aneurysms]]
- [[hypopituitarism]] for other hormones
- Psychological: Depresssion
### Treatment
Here's a table summarizing the treatment options and follow-up measures for acromegaly:

| Treatment    | Description                                                                                                                                                                                                                                                          |
| ------------ | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| Surgery      | - [[Transsphenoidal adenomectomy]] (preferred method) <br> - Surgical debulking (in patients with parasellar disease and inoperable tumors)                                                                                                                          |
| Medication   | - [[Somatostatin]] analogs (e.g., octreotide, lanreotide) <br> - [[Dopamine agonists]] (e.g., cabergoline): reduce tumor size and GH secretion <br> - GH receptor antagonists (e.g., pegvisomant)                                                                    |
| Radiotherapy | - Conventional fractionated radiotherapy <br> - [[Stereotactic radiosurgery]] (e.g., Gamma Knife, CyberKnife, proton beam)                                                                                                                                           |
| Follow-up    | - Assessing IGF-1 and random GH level 12 weeks after the surgery and then annually <br> - Annual hormonal testing for [[hypopituitarism]] <br> - Performing MRI at least 12 weeks after the surgery <br> - Serial imaging with MRI in patients receiving pegvisomant |

### Differential diagnosis
- [[Gigantism]]: excess GH secretion in children, before epiphyseal plate closure
- [[Marfan syndrome]]
- [[Pseudoacromegaly]] (e.g., medication-induced): insulin resistance, acromegaloid features, normal GH and IGF-1
- [[Prolactinoma]]: pituitary tumor; excess of prolactin, not GH
- [[Familial tall stature]]
- [[Sotos syndrome]]
- [[McCune-Albright syndrome]]

---
